Ceribell (CBLL) Net Income towards Common Stockholders (2023 - 2026)

Ceribell (CBLL) posted Net Income towards Common Stockholders of -$19.7 million for Q1 2026, down 45.91% on a QoQ basis from -$13.5 million in Q4 2025, and down 54.47% year-over-year from -$43.4 million in Q1 2025.

Ceribell (CBLL) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends

Ceribell's Net Income towards Common Stockholders history runs 4 years deep, the most recent figure standing at -$19.7 million for Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 54.47% year-over-year to -$19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$60.4 million (down 35.03% YoY) and the FY2025 annual result came in at -$54.0 million, down 69.15% from the prior year.
  • Net Income towards Common Stockholders was -$19.7 million for Q1 2026 at Ceribell, down from -$13.5 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$7.1 million in Q3 2023 and bottomed at -$19.7 million in Q1 2026.
  • A 4-year average of -$11.7 million and a median of -$12.6 million in 2024 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders fell 7.56% — and 2026, when it slumped 54.47%.
  • Ceribell's Net Income towards Common Stockholders stood at -$8.3 million in 2023, then tumbled by 51.99% to -$12.6 million in 2024, then dropped by 7.56% to -$13.5 million in 2025, then plunged by 45.91% to -$19.7 million in 2026.
  • Business Quant data shows CBLL's Net Income towards Common Stockholders at -$19.7 million in Q1 2026, -$13.5 million in Q4 2025, and -$13.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Abbott Laboratories 183.86 Bn 176.56 Bn 6.27 Bn 1.08 Bn
2 Stryker 128.65 Bn 125.78 Bn 3.81 Bn 745.00 Mn
3 Medtronic 108.75 Bn 99.53 Bn 6.41 Bn 1.26 Bn
4 Boston Scientific 68.34 Bn 66.89 Bn 3.61 Bn 1.34 Bn
5 Edwards Lifesciences 48.33 Bn 44.65 Bn 1.29 Bn -
6 GE HealthCare Technologies 28.35 Bn 26.07 Bn 1.98 Bn 411.00 Mn
7 Dexcom 28.33 Bn 27.21 Bn 750.30 Mn 199.50 Mn
8 Smith & Nephew 26.90 Bn 26.32 Bn - -
9 Koninklijke Philips 25.45 Bn 22.33 Bn 2.07 Bn 176.78 Mn
10 Ceribell 673.42 Mn 532.24 Mn 23.12 Mn -19.74 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -19.74 Mn
Dec 31, 2025 -13.53 Mn
Sep 30, 2025 -13.47 Mn
Jun 30, 2025 -13.64 Mn
Mar 31, 2025 -12.78 Mn
Dec 31, 2024 -12.58 Mn
Sep 30, 2024 -10.42 Mn
Jun 30, 2024 -8.94 Mn
Mar 31, 2024 -8.52 Mn
Dec 31, 2023 -8.27 Mn
Sep 30, 2023 -7.05 Mn